Description overdue on 30.01.2012

Hepatoprotectors . Main, an active substance - ademetionine . Geptral has a protective, holekineticheskoe, choleretic, weakly expressed anti-depressive effects. The mechanism of action of the drug aims to cover the deficit ademetionine, stimulating its production by liver cells and brain. Geptral is the donor of the methyl group has been actively involved with the biological reactions transmethylation . The drug donates a methyl group in the process of methylation of phospholipids of cell membranes proteins neurotransmitters Hormones. Geptral involved in the process transsulfatirovaniya . Ademetionine normalizes metabolism in the liver system, reduces the number of methionine   in the blood increases glutamine   in the hepatic system, Taurine   and   cysteine   in blood plasma. After the process of decarboxylation   Geptral participates in aminopropilirovanii , Representing putrescine (polyamine predecessors), which stimulates the process of hepatocyte proliferation, cell regeneration. Ademetionine has choleretic effect That provides increased mobility, the polarization of cell membranes by stimulating production of gapatotsitov phosphatidylcholine   therein. The mechanism of action of the drug promotes the passage of bile acids in the bile ducts, improve transport function bile acids . Marked efficacy seen with intralobular form cholestasis , In violation of generation and outflow of bile. Geptral increases sulfated conjugated bile acids in hepatocytes promotes detoxification of bile acids.

Through conjugation with taurine increases the solubility of bile acids improves their removal from the hepatocyte cells. When sulphation bile acids increased their elimination   renal system to facilitate their passage through the cell membrane of hepatocytes, bile excretion from the shock. Sulfated bile kiloty exert a protective effect on the liver cell membrane system, protecting them from adverse, toxic effects of non-sulfonated bile acids (with intrahepatic cholestasis are present in high concentrations).

In patients with hepatitis, cirrhosis , Diffuse diseases of the liver system intrahepatic cholestasis   reduced levels of hepatic transaminases, alkaline phosphatase, direct bilirubin, reduced the severity of itching. After discontinuation hepatoprotective and choleretic effects persist for three months. In patients with opioid addiction syndrome diseased liver marked regression of signs withdrawal , Improved processes microsomal oxidation It improves the functional state of the liver. The antidepressant effect of the drug begins to emerge by the end of the first week of therapy, develops gradually and stabilized within 15 days of treatment. Geptral effective for the recurrent form of neurotic and endogenous depression resistant to amitriptyline . The drug is able to interrupt recurrences of depression. At   osteoarthritis   reduces the severity of pain attack, partially improves the regeneration of cartilage tissue, increases the production of proteoglycans . Geptral available in tablet form, as a lyophilisate.

Indications and contraindications:

Geptral prescribed for intrahepatic cholestasis, cholangitis . cholecystitis , Toxic liver disease of viral, drug, alcoholic genesis. The drug is effective in alcohol withdrawal, depression, encephalopathy, liver cirrhosis, chronic hepatitis, fatty liver . The drug is not indicated during breastfeeding, hypersensitive ademetionine, pregnancy. In pediatric practice used with caution.

Side effect:

Use of the drug can provoke heartburn . dyspepsia . stomachalgia Allergic reactions.

Mode of application:

Geptral used intramuscularly, intravenously, orally. Intensive care: daily 400-800 mg intravenously / intramuscularly for 3 weeks ex. Prior to administration the powder is diluted in a solution of L-lysine, attached to a vial with lyophilized. Supportive therapy: 800-1600 mg daily in the morning, do not chew.

Special instructions:

Geptral not recommended for use before bedtime. In patients with cirrhosis of the liver on the background hyperasotemia   Treatment is recommended for regular monitoring of nitrogen. Long-term treatment requires an assessment of the level creatinine . urea . The solution for injection is prepared exclusively prior to administration.